A multicenter approach to evaluate omalizumab effectiveness in Samter's triad

Area of Science:

• Immunology
• Pulmonology
• Allergy

Background:

• Severe atopic asthma control is challenging.
• Omalizumab shows promise for aspirin-exacerbated respiratory disease (AERD).
• Samter's triad (asthma, nasal polyposis, AERD) requires effective management.

Purpose of the Study:

• To evaluate omalizumab's effectiveness in a multicenter cohort of patients with Samter's triad.
• To assess clinical outcomes, functional parameters, and symptom control.

Main Methods:

• Retrospective enrollment of eight patients with Samter's triad.
• Minimum one-year omalizumab therapy.
• Collection of clinical data, FEV1, and validated questionnaires at baseline and follow-up.

Main Results:

• Significant reduction in moderate-to-severe asthma exacerbations.
• Increased FEV1 (Forced Expiratory Volume in 1 second).
• Decreased need for oral steroid therapy.
• Improved asthma control and nasal symptom scores.

Conclusions:

• This multicenter study confirms omalizumab's effectiveness in Samter's triad.
• Omalizumab offers a potential therapeutic option for managing Samter's triad.
• Further research may solidify its role in AERD management.